Talk:Ocrelizumab
| This is the talk page for discussing improvements to the Ocrelizumab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ocrelizumab.
|
questionable deletion
Someone deleted most of my update :
"On October 8th, 2015, Genentech announced the results of three large Phase III clinical trials. Ocrelizumab (given as 600mg IV every 6 months) was shown in the OPERA I/II trials to reduce multiple sclerosis relapses by 47% (and also slowed progression of the disease) when compared to Rebif (a thrice weekly injection).[1] In the ORATORIO trail for primary progressive MS ocrelizumab (600mg IV every 6 months) slowed the progression of the disease by 24% compared to placebo.[1] Genentech expect to apply for European marketing authorisation in early 2016.[1]"
saying "need a better ref than a paraphrasing of a press release". It might have been more constructive to look for, or ask for, a better reference rather than deleting useful material. The 'press release' got wide coverage (eg [1], [2] and reports on MS charity websites). ECTRIMS Conference commentary abstracts : ORATORIO, OPERA I/II. I wonder if these would be considered better enough. Academic journal reports should be available within a few weeks of the conference. - Rod57 (talk) 12:05, 6 November 2015 (UTC)
CMSC meetings
Here's the abstract from the 2016 Consortium of Multiple Sclerosis Centers annual meeting:
https://cmsc.confex.com/cmsc/2016/webprogram/Paper4221.html
Ocrelizumab Efficacy in PPMS Patients in the Presence/Absence of T1 Gadolinium-Enhancing Lesions at Baseline in a Phase III, Placebo-Controlled Trial
Friday, June 3, 2016: 3:15 PM
Jerry Wolinsky, MD et al.
Conclusions: In ORATORIO, OCR reduced clinical and MRI disease activity vs PBO, including in patient subgroups with and without T1 Gd+lesions at baseline.
http://www.medpagetoday.com/meetingcoverage/cmsc/58342
Meeting Coverage cme/ce
Novel Agent Works in Primary Progressive MS
Ocrelizumab cuts progression risk by 24%, study finds
Medpage Today
Here's the NEJM report:
http://www.nejm.org/doi/full/10.1056/NEJMoa1606468
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban, et al.
December 21, 2016
DOI: 10.1056/NEJMoa1606468
Conclusions
Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab. (Funded by F. Hoffmann–La Roche; ORATORIO ClinicalTrials.gov number, NCT01194570.)
--Nbauman (talk) 08:09, 3 January 2017 (UTC)
A generally favorable article:
- Medical News & Perspectives
- New Inroads Against Multiple Sclerosis
- Jeff Lyon
- JAMA. 2018;319(1):9-11.
- January 2, 2018
- doi:10.1001/jama.2017.14033
- --Nbauman (talk) 19:50, 15 January 2018 (UTC)
Cost of the drug being mentioned and the general Article Layout
I just modified the intro, written by someone else, about the 65.000$ price tag, and added the per-year information. However had, this actually already came up twice within the same article, so this is a bit redundant. I'd suggest that the intro part about the price, is moved into its own subsection within the article, rather than be there at the very start of the article. Right now we have had the same info two times and it should suffice to have it only once. 2A02:8388:1641:4700:BE5F:F4FF:FECD:7CB2 (talk) 16:41, 4 May 2017 (UTC)